Condition

Cancer Prostate

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 12 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials12

Recruiting1

Common interventions17

Lead sponsors shown12

Clinical trials

12 shown

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryNCT03452774 · 2018-01-01

RECRUITING

Evaluation of the Medical Service by Socio-aesthetics in OncologyNCT06035731 · 2024-05-15

COMPLETED

Patient Education Videos to Improve Patients' Experience During Radiotherapy Treatment: a National ProjectNCT06152419 · 2023-10-17

UNKNOWN

Prospective Validation of PSMA-RADSNCT06359717 · 2023-01-01

ACTIVE_NOT_RECRUITING

Diet Effect on Cancer Treatment OutcomeNCT05410002 · 2022-10-12

COMPLETED

Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic MalignancyNCT05154474 · 2022-06-01

UNKNOWN

Quest to Analyze One Thousand Humans MeditatingNCT06583395 · 2021-12-05

ENROLLING_BY_INVITATION

Comorbidities And Reducing inEquitieSNCT04836221 · 2021-05-05

COMPLETED

Physical Activity Experiment on Male Prostate Cancer PatientsNCT03866785 · 2018-08-02

COMPLETED

Volatile Anaesthesia and Perioperative Outcomes Related to Cancer Feasibility StudyNCT04074460 · 2017-08-27

COMPLETED

Assessment of a New Fluorescence Imaging Technique Using Biopsies From Prostate ResectionNCT03157856 · 2017-05-11

TERMINATED

Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone TherapyNCT00172055 · 2004-12-01

COMPLETED

Common interventions

Activity actigraphDEVICE1 Adult Physical Activity Questionnaire (APAQ)DIAGNOSTIC_TEST1 Advanced multi-component meditation practiceBEHAVIORAL1 Clinical Trial MatchingOTHER1 Dietary Supplement: N-111DIETARY_SUPPLEMENT1 Fluorescence assessmentOTHER1 interviewDIAGNOSTIC_TEST1 isoflurane, sevoflurane or desfluraneDRUG1 Peer trainingOTHER1 Physical Activity ProgramOTHER1 PlaceboOTHER1 PropofolDRUG1 QuestionnaireDEVICE1 SOCIO-AESTHETICS careOTHER1 StandardOTHER1 SupportBEHAVIORAL1 Zoledronic acidDRUG1

Mapped drugs appearing in these trials

Shared trial participation only; not evidence of efficacy or approval.

propofol1 zoledronic acid1

Leading sponsors

Centre Hospitalier de Valence 1 Centre Hospitalier Universitaire de Saint Etienne 1 Massive Bio, Inc. 1 Medstar Health Research Institute 1 Novartis Pharmaceuticals 1 Optimal Health Research 1 Peter MacCallum Cancer Centre, Australia 1 Tobias Moeller-Bertram 1 University Hospital, Ghent 1 University Hospital, Grenoble 1 Weprom 1 Zagazig University 1

Trial status mix

COMPLETED6

UNKNOWN2

ACTIVE_NOT_RECRUITING1

ENROLLING_BY_INVITATION1

RECRUITING1

TERMINATED1

Phase mix

NA4

PHASE11

PHASE31

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.